Incyte
INCY

$61.26

3.18%

Market Cap: $11.8B

About: Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Employees: 2,524

Industrials Commercial Physical & Biological Research

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 9 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

22% more call options, than puts

Call options by funds: $51.7M | Put options by funds: $42.3M

1% more repeat investments, than reductions

Existing positions increased: 218 | Existing positions reduced: 216

0% more funds holding in top 10

Funds holding in top 10: 5 [Q1] → 5 (+0) [Q2]

0% less funds holding

Funds holding: 566 [Q1] → 565 (-1) [Q2]

1% less first-time investments, than exits

New positions opened: 73 | Existing positions closed: 74

4% less capital invested

Capital invested by funds: $12.4B [Q1] → $12B (-$445M) [Q2]

9.29% less ownership

Funds ownership: 97.08% [Q1] → 87.79% (-9.29%) [Q2]

See Fund Rankings

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$48

22%

downside

Avg. target

$67

10%

upside

High target

$88

44%

upside

9 analyst ratings

2 positive

22%

6 neutral

67%

1 negative

11%

RBC Capital Brian Abrahams 52% 1-year accuracy 39 / 75 met price target	9%upside $67	Sector Perform Reiterated	3 Sept 2024
RBC Capital Brian Abrahams 52% 1-year accuracy 39 / 75 met price target	9%upside $67	Sector Perform Maintained	15 Aug 2024
Deutsche Bank James Shin 100% 1-year accuracy 5 / 5 met price target	2%downside $60	Hold Maintained	1 Aug 2024
Citigroup David Lebowitz 50% 1-year accuracy 9 / 18 met price target	44%upside $88	Buy Maintained	31 Jul 2024
JP Morgan Jessica Fye 62% 1-year accuracy 23 / 37 met price target	0%downside $61	Neutral Maintained	31 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 10 articles about INCY published over the past 30 days

Zacks Investment Research

Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue?

Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at ESMO Congress 2024.

Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Incyte Corporation reported positive results achieved from Phase 3 study using Monjuvi for the treatment of patients with relapsed/refractory follicular lymphoma. Supplemental Biologics License Application filing for label expansion of Monjuvi for the treatment of patients with relapsed/refractory follicular lymphoma, expected by end of 2024. It is expected that the 7 major follicular lymphoma markets are expected to reach a value of $2.2 billion by 2034.

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Zacks Investment Research

Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug

Incyte???s (INCY) late-stage study on tafasitamab for patients with relapsed or refractory follicular lymphoma meets its goal. FDA approves axatilimab for the treatment of chronic graft-versus-host disease.

Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug

Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study

On Friday, Incyte Corporation INCY released topline results from the pivotal Phase 3 inMIND trial evaluating the efficacy and safety of Monjuvi (tafasitamab) and lenalidomide as an add-on to rituximab compared with lenalidomide alone as an add-on to rituximab in patients with relapsed or refractory follicular lymphoma or relapsed or refractory nodal, splenic or extranodal marginal zone lymphoma (MZL).

Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study

Incyte's blood cancer drug succeeds late-stage trial

Incyte said on Thursday its drug met the main goal in a late-stage trial evaluating it in patients with a form of blood cancer.

Incyte's blood cancer drug succeeds late-stage trial

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma.

$Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma$

Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

WILMINGTON, Del. & WALTHAM, Mass.--(BUSINESS WIRE)---- $INCY--Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD).

Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

FDA approves Incyte's treatment for chronic graft-versus-host disease

The U.S. Food and Drug Administration on Wednesday approved drugmaker Incyte Corp's treatment for a type of graft-versus-host disease (GvHD).

FDA approves Incyte's treatment for chronic graft-versus-host disease

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 at 12:45 pm (EDT) Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6, 2024 at 10:45 am (EDT) Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 9:45 am (EDT) The presentations will be webcast live and can be accessed at Inv.

Incyte to Present at Upcoming Investor Conferences

See News Rankings